(1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl)(2-chloropyrimidin-5-yl)methanol | 1208315-12-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl)(2-chloropyrimidin-5-yl)methanol
• 英文别名: [5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-(2-chloropyrimidin-5-yl)methanol
• CAS: 1208315-12-1
• 化学式: C₂₁H₁₄Cl₄N₄O
• 分子量: 480.18
• InChiKey: FXPGNRWNUSZJPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] 1,5-DIARYL-PYRAZOLES AND THEIR USE AS CANNABINOID RECEPTOR NEUTRAL ANTAGONISTS<br/>[FR] 1,5-DIARYL-PYRAZOLES ET LEUR UTILISATION COMME ANTAGONISTES NEUTRES DES RÉCEPTEURS CANNABINOÏDES
  申请人：UNIV ABERDEEN

  公开号：WO2010020762A1

  公开（公告）日：2010-02-25

  The present invention pertains to cannabinoid (CB) receptor and cannabinoid-like receptor neutral antagonists, and especially CB1 neutral antagonists of Formula (I). The present invention also pertains to these compounds for use in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor or a non-CB1/non-CB2 cannabinoid-like receptor, for example: an eating disorder; obesity; cardiovascular disease; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget' s disease of bone; bone related cancer; breast cancer; breast cancer metastases; breast cancer which has metastasised to bone; cancer associated with activation or inactivation of a non-CB1/non-CB2 cannabinoid-like receptor,

  本发明涉及大麻素（CB）受体和类大麻素受体中和拮抗剂，特别是公式（I）的CB1中和拮抗剂。本发明还涉及这些化合物在治疗通过使用大麻素类型1（CB1）受体的中和拮抗剂或非CB1/非CB2类大麻素受体得到改善的疾病和疾病的使用，例如：进食障碍；肥胖；心血管疾病；由成瘾成分特征的疾病或障碍；成瘾；戒断；吸烟成瘾；戒烟；药物成瘾；戒毒；戒烟疗法；骨骼疾病或障碍；骨质疏松症，Paget骨病；与激活或失活非CB1/非CB2类大麻素受体相关的癌症。